Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cacaito who wrote (232)	1/27/1998 8:57:00 PM
From: Dr. John M. de Castro	Read Replies (1) of 1494

The composition of matter patent for memantine has expired. The only patent protection available for memantine are use patents. Allergan has the rights to the use of memantine for opthalamic indications. As I remember, their rights are restricted to just these indications. This is not a threat to NTII. IMO it is another endorsement of how useful memantine is. John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next